Head-to-head · WeighScore
He & She MD vs Maves
The verdict
Maves takes it — 71.6/100 to 71.5/100, but only just.
Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with… He & She MD is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | He & She MD | Maves |
|---|---|---|
| WeighScore | 71.5/100 | 71.6/100 |
| Grade | C | C |
| Scorecard rank | #92 | #91 |
| Semaglutide | $139/mo (starting dose, promotional rate, compounded) | $99/mo (starting dose, first-month rate, compounded) |
| Tirzepatide | $199/mo (starting dose, compounded) | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #92 · C
Strengths
- Transparent intro pricing: injectable GLP-1 from $139/month, oral from $199, microdose from $99
- Compounded semaglutide and tirzepatide (injectable or oral) plus brand access to Ozempic, Wegovy, Zepbound
- Only charged if medication is prescribed; no hidden fees
- Free expedited shipping and unlimited board-certified clinician access
- GLP-1 coaching, nutrition guidance, and in-app progress tracking
Where it loses points
- Compounded GLP-1s are not FDA-approved finished products (per the site FDA disclaimer)
- Does not ship to Louisiana or to PO boxes
- Introductory pricing rises after the 6-month (or 3-month microdose) plan
- Cash-pay model — insurance billing not indicated
Graded #91 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.